Disclosure under Regulation 7(2) of SEBI (Prohobition of Insider Trading) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudhir Sethi, the main Promoter and Director of Beryl Drugs Ltd, has acquired 4,853 shares of the company, representing 0.10% of the total shareholding. This disclosure was filed under Regulation 7(2) of SEBI's Prohibition of Insider Trading Regulations, 2015, with the Bombay Stock Exchange. The transaction was reported by the company on March 12, 2026. The acquisition is a small buy by the promoter in the open market.
The promoter is incrementally increasing their stake, which is generally viewed as a positive signal showing insider confidence. However, the size of the purchase is very small (0.10%) and unlikely to materially impact the stock price or change the promoter's overall holding meaningfully.